Intravenous administration of CP-4055 (ELACYT™) in patients with solid tumours. A phase I study

Acta Oncologica

Volumn 48, Issue 1, 2009, Pages 137-145

  Dueland, Svein ^a   Aamdal, Steinar ^a   Lind, Michael J ^b   Thomas, Hilary ^c   Liland Sandvold, Marit ^d   Gaullier, Jean Michel ^d   Rasch, Wenche ^d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b PRINCESS ROYAL HOSPITAL   (United Kingdom)

^c ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^d Clavis Pharma ASA   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CP 4055; CYTARABINE; ELACYT; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MELANOMA; MIDDLE AGED; NEOPLASMS; OVARIAN NEOPLASMS;

EID: 58149095946     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802183620     Document Type: Article

References (27)

1. Francis SO, Mahlberg MJ, Johnson KR, Ming ME, Dellavalle RP. Melanoma chemoprevention. J Am Acad Dermatol 2006;55:849-61.
2. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: Time for a change? Cancer 2007;109:455-64.
3. Kasper B, D'Hondt V, Vereecken P, Awada A. Novel treatment strategies for malignant melanoma: A new beginning? Crit Rev Oncol Hematol 2007;62:16-22.
4. Chan JK, Cheung MK, Husain A, Teng NN, West D, Whittemore AS, et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol 2006;108:521-8.
5. Herzog TJ, Pothuri B. Ovarian cancer: A focus on management of recurrent disease. Nat Clin Pract Oncol 2006;3:604-11.
6. Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, et al. Ovarian cancer. Crit Rev Oncol Hematol 2006;60:159-79.
7. Subramanian J, Govindan R. Lung cancer in never smokers: A review. J Clin Oncol 2007;25:561-70.
8. Juergens RA, Brahmer JR. Adjuvant treatment in non-small cell lung cancer. Where are we now? J Natl Compr Canc Netw 2006;4:595-600.
9. Lister TA, Rohatiner AZ, Bassan R, Gregory W, Willis L, Barnett MJ, et al. Conventional dose cytosine arabinoside in combination chemotherapy for acute myelogenous leukaemia. Semin Oncol 1987;14:53-4.
10. Bolwell BJ, Cassileth PA, Gale RP. High dose cytarabine: A review. Leukaemia 1988;2:253-60.
11. Plunkett W, Gandhi V. Cellular pharmacodynamics of anticancer drugs. Semin Oncol 1993;20:50-63.
12. Rustum YM, Raymakers RA. 1-Beta-arabinofuranosylcytosine in therapy of leukaemia: Preclinical and clinical overview. Pharmacol Ther 1992;56:307-21.
13. Grant S. Ara-C: Cellular and molecular pharmacology. Adv Cancer Res 1998;72:197-233.
14. Gailani S, Nussbaum A. Correlation of response to 1-beta-D- arabinofuranosyl cytosine and metabolism of drug by tumour. J Med 1976;7:93-102.
15. Bajetta E, Verusio C, Bonfante V, Bonadonna G. Cytarabine and cisplatin in advanced malignant melanoma. Cancer Treat Rep 1986;70:1441-2.
16. th ed. Philadelphia: JB Lippincott Co; 1993. p. 365-9.
17. Someya H, Waud WR, Parker WB. Long intracellular retention of 4′-thio-arabinofuranosylcytosine 5′-triphosphate as a critical factor for the antisolid tumour activity of 4′- thioarabinofuranosylcytosine. Cancer Chemother Pharmacol 2006;57:772-80.
18. Breistøl K, Balzarini J, Sandvold ML, Myhren F, Martinsen M, De Clercq F, et al. Antitumour activity of P-4055 (Elaidic Acid-Cytarabine) compared to cytarabine in metastatic and s.c. human tumour xenograft models. Cancer Res 1999;59:2944-9.
19. Ross DD, Chen SR, Cuddy DP. Effects of 1-beta-D-arabinofuranosylcytosine on DNA replication intermediates monitored by PH-step alkaline elution. Cancer Res 1990;50:2658-66.
20. Bergman AM, Kuiper CM, Voorn DA, Comijn EM, Myhren F, Sandvold ML, et al. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukaemia and solid tumour cell lines. Biochem Pharmacol 2004;67:503-11.
21. Bergman AM, Kuiper CM, Myhren F, Sandvold ML, Hendriks HR, Peters GJ. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (ara-C) in leukaemia and solid tumour cell lines. Nucleosides Nucleotides Nucleic Acids 2004;23:1523-6.
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumours. J Natl Cancer Inst 2000;92:205-16.
23. Delaunoit T, Raymond E, Awada A, Savinelli F, Culine S, Rasch W, et al. A three schedule phase I trial of CP-4055, weekly and q2 weeks in patients with advanced or metastatic solid tumors. J Clin Oncol 2006;(Suppl):2067 (abstract).
24. Stentoft J. The toxicity of cytarabine. Drug Safety 1990;5:7-27.
25. Peters WG, Colly LP, Willemze R. High-dose cytosine arabinoside: Pharmacological and clinical aspects. Blut 1988;56:1-11.
26. Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP. High-dose cytosine arabinoside therapy for refractory leukaemia. Blood 1983;62:361-9.
27. Capizzi RL, White JC, Powel BL, Perrino F. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine. Semin Hematol 1991;28:54-69.